Brief report · 30 Nov 2025
ArticlePublished 22 Dec 2021
A Broadspectrum Of Posaconazole Against Fungal Infections
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Posaconazole is a pinch- generation triazole agent with a potent and broad antifungal in vitro exercise against a range of different Candida species, Aspergillus species, Cryptococcus neoformans, the zygomycetes, and other filamentous fungi. Rfungal pathogens, including Aspergillusspp. and Candida spp. It's structurally related to itraconazole and inhibits lanosterol 14α-demethylase (CYP51), blocking the compound of ergosterol behaving in disabled cell membrane stability and accumulation of precursors leading to fungistatic or fungicidal paraphernalia. Posaconazole (Noxafil, Schering Corporation, Kenilworth, NJ) was approved by the Food and Drug Administration for use as prophylaxis against invasive Aspergillus and Candida infections in immunocompromised case. Posaconazole differs in structure from the compact triazoles fluconazole and voriconazole in part by virtue of its extended side chain, a affection held in common with itraconazole.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Biomedical and Pharmaceutical Sciences.
Article · 29 Nov 2025
Mechanisms of Cancer Drug Resistance and Overcoming Them
Article · 29 Nov 2025
Tumor Microenvironment: Key to Cancer Progression and Therapy
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Biomedical and Pharmaceutical Sciences
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Tosin Adetobi”
